AVXL

Business Context and Reporting Period

Company: Anavex Life Sciences Corp.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Stage: Development Stage Company (No revenue generated since inception in 2004).
Operations: The company is engaged in the discovery and development of novel drug targets (SIGMACEPTOR platform) for neurodegenerative diseases (e.g., Alzheimer's) and cancer. Lead candidate ANAVEX 2-73 is in preclinical stages with Human Clinical Trials (HCT) expected in 2010.

Key Financial Metrics

Material Changes vs. Prior Period

• Expense Increase: Total expenses for the three months ended March 31, 2010, increased by $747,879 compared to the same period in 2009. This was driven primarily by:
  • Research & Development: Increased from $328,859 to $815,609 due to expanded research activities.
  • Consulting Fees: Increased from $430,964 to $568,816, largely due to higher stock-based compensation charges.
  • Legal Fees: Increased from $1,911 to $17,775 due to patent and corporate activity.
• Derivative Liability Impact: The company adopted new accounting policies (ASC 815-40-15) effective October 1, 2009, requiring embedded conversion features in promissory notes to be classified as derivative liabilities. This resulted in a non-cash gain of $560,214 for the six months ended March 31, 2010, compared to nil in the prior year.
• Cash Position: Cash decreased by $206,484 from September 30, 2009 ($350,994) to March 31, 2010 ($144,510), primarily due to increased R&D expenditures.
• Debt Structure: Issued a new $1,000,000 convertible promissory note at 20% interest during the quarter.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: The filing explicitly states substantial doubt about the company's ability to continue as a going concern due to an accumulated deficit of nearly $15 million and a history of losses. Continued operations depend on securing additional financing.
• Capital Requirements: Management anticipates requiring up to $10 million for the 12 months ending March 31, 2011, to fund clinical trials for ANAVEX 2-73 and other compounds.
• Unusual Items:
  • Accounting Change: A cumulative effect adjustment of $589,032 was recognized in the prior fiscal year due to the reclassification of embedded conversion features as derivative liabilities.
  • Stock Settlement: Settled a $100,000 promissory note by issuing 49,505 common shares in February 2010.
• Risks:
  • Failure to secure additional financing could force the company to delay or cease operations.
  • High risk associated with preclinical drug development; no assurance of regulatory approval or commercial success.
  • Volatility in earnings due to the mark-to-market accounting of derivative liabilities linked to stock price fluctuations.
  • Disclosure controls and procedures were deemed ineffective as of the end of the period.

Investor Verification Checklist

• Liquidity Runway: Verify if the $144,510 cash balance is sufficient to cover immediate obligations given the $4.4 million working capital deficit.
• Financing Status: Confirm the status of the anticipated $10 million funding requirement and any committed sources of capital.
• Debt Maturities: Review the maturity dates of the $3.58 million in promissory notes, several of which are due on demand or have matured as of March 31, 2010.
• Derivative Liability Volatility: Assess the impact of future stock price movements on the company's reported net income due to the mark-to-market valuation of derivative liabilities.
• Clinical Milestones: Monitor the timeline for the Investigational New Drug (IND) filing and the start of Human Clinical Trials for ANAVEX 2-73.